GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Endonovo Therapeutics Inc (OTCPK:ENDV) » Definitions » Cash From Discontinued Investing Activities

Endonovo Therapeutics (Endonovo Therapeutics) Cash From Discontinued Investing Activities : $0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Endonovo Therapeutics Cash From Discontinued Investing Activities?

Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Endonovo Therapeutics's cash from discontinued investing activities for the three months ended in Dec. 2023 was $0.00 Mil. It means Endonovo Therapeutics received $0.00 Mil from discontinued investing activities. Endonovo Therapeutics's cash from discontinued investing activities for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.


Endonovo Therapeutics Cash From Discontinued Investing Activities Historical Data

The historical data trend for Endonovo Therapeutics's Cash From Discontinued Investing Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endonovo Therapeutics Cash From Discontinued Investing Activities Chart

Endonovo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash From Discontinued Investing Activities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Endonovo Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash From Discontinued Investing Activities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Endonovo Therapeutics Cash From Discontinued Investing Activities Calculation

Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Cash From Discontinued Investing Activities for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Endonovo Therapeutics Cash From Discontinued Investing Activities Related Terms

Thank you for viewing the detailed overview of Endonovo Therapeutics's Cash From Discontinued Investing Activities provided by GuruFocus.com. Please click on the following links to see related term pages.


Endonovo Therapeutics (Endonovo Therapeutics) Business Description

Industry
Traded in Other Exchanges
N/A
Address
6320 Canoga Avenue, 15th Floor, Woodland Hills, CA, USA, 91367
Endonovo Therapeutics Inc is an us-based biotechnology company that focuses on the business of biomedical research and development, particularly in regenerative medicine, which has included the development of its proprietary square waveform device. It is engaged in developing the Immunotronics platform which is non-implantable, a non-invasive medical device to target inflammatory conditions in vital organs; and the Cytotronics platform which uses Time-Varying Electromagnetic Fields technology for the creation of cell-based therapies. The company generates its revenue through its technology licensing and commercialization activities.
Executives
Alan Brian Collier director, 10 percent owner, officer: CEO 6320 CANOGA AVENUE, 15TH FLOOR, WOODLAND HILLS CA 91367
Michael Scott Mann 10 percent owner, officer: President 6320 CANOGA AVENUE, WOODLAND HILLS CA 91367

Endonovo Therapeutics (Endonovo Therapeutics) Headlines

From GuruFocus

Endonovo Launches SofPulse� into the Veterans Administration

By sperokesalga sperokesalga 05-02-2023

Endonovo Partners with International Distributor for SofPulse� Line

By Stock market mentor Stock market mentor 01-26-2023

New Details on Endonovo's Spin-Off of SofPulse, Inc.

By Stock market mentor Stock market mentor 01-19-2023

Endonovo Launches Telehealth Initiative

By Value_Insider Value_Insider 12-13-2022